Lokavant trained algorithms for clinical-trial risk monitoring

The same prospectus says Roivant aggregated clinical-trial technologies at its subsidiary Lokavant. It says algorithms trained on operational metadata from over 2,000 trials are designed to identify the most important risks in time for researchers to intervene, and that Lokavant's software is in use in Roivant's late-stage trials and in trials run by other sponsors and contract research organizations.